Zymeworks’ HER2 Antibody Hits Target In Pivotal Biliary Tract Cancer Trial

First-In-Class Potential In Disease

 
• By Ayisha Sharma
  
3D Animation of antibodies
Zanidatamab Is A Bispecific Antibody That Targets HER2 • Source: Shutterstock

More from Clinical Trials

More from R&D